Clinical Pharmacology of Miami

Summary

Clinical Pharmacology of Miami is a medical facility located in Hialeah, Florida. This center is recognized for care of Healthy Subjects, Liver disease, Renal Disease, Kidney Failure, Type 2 Diabetes and other specialties. Clinical Pharmacology of Miami is involved with conducting 226 clinical trials across 166 conditions. There are 3 research doctors associated with this hospital, such as Alexander Prezioso, Alfredo Fernandez, and Ernesto Fuentes.

Top PIs

Clinical Trials running at Clinical Pharmacology of Miami

Liver disease

Alzheimer's Disease

Healthy Subjects

Liver Dysfunction

Obesity

Psychotic Episodes

Renal Disease

Autoimmune disorders

Cardiometabolic Diseases

Quizartinib

for Liver Disease

This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.

Recruiting

1 award

Phase 1

2 criteria

Mirdametinib

for Liver Disease

The purposes of this study are to determine: * The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug. * How well the study drug is tolerated and any side effects that may occur in participants with moderate or severe liver function impairment compared to participants with normal liver function. This study is for research purposes only and is not intended to treat any medical condition.

Recruiting

1 award

Phase 1

2 criteria

Nemtabrutinib

for Liver Disease

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.

Recruiting

1 award

Phase 1

2 criteria